CSIMarket


Axim Biotechnologies Inc   (AXIM)
Other Ticker:  
 


 

Axim Biotechnologies Inc

AXIM's Financial Statements and Analysis



Axim Biotechnologies Inc reported in the third quarter of 2023 net earnings per share of $0.00 an improvement compare to net loss per share of $-0.01 recorded a year ago and an improvement compare to net loss per share of $-0.02 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ 0 $  0 Mill
$+0.01     Unch.     +629.15 %



Axim Biotechnologies Inc 's Revenue rose by 629.15 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by -3.5 % sequentially.


Axim Biotechnologies Inc is Expected to report next financial results on April 16, 2024.

More on AXIM's Income Statement



Axim Biotechnologies Inc 's net income of $0.657 million in the third quarter of 2023 increased from net loss of $-2.035 million III. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-3.723 million recorded in previous quarter.

More on AXIM's Growth

Axim Biotechnologies Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $0 million


Axim Biotechnologies Inc does not pay out common stock dividend.

In trailing twelve-month period Axim Biotechnologies Inc payed $ 0.00 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.02 per share from $ -0.06.

Company issued 252.24 million shares or 111.48 % in Sep 30 2023.


More on AXIM's Dividends

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 479
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Axim Biotechnologies Inc does not pay out common stock dividend.

In trailing twelve-month period Axim Biotechnologies Inc had negative $ 0.00 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.02 per share from $ -0.06.

Company issued 252.24 million shares or 111.48 % in Sep 30 2023.


More on AXIM's Balance Sheets

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 479
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Axim Biotechnologies Inc Earnings

Axim Biotechnologies Inc Shatters Expectations with Record-Breaking Numbers for Fiscal Q3 2023

Axim Biotechnologies Inc, a leading player in the biotech industry, has showcased impressive performance in the fiscal third quarter of 2023. While many businesses in the Major Pharmaceutical Preparations sector have struggled with dwindling revenues and diminishing top-line, Axim Biotechnologies Inc has managed to achieve a remarkable turnaround.
The company reported balanced books in the fiscal third quarter of 2023, with earnings per share reaching $0.00. This is a significant improvement compared to the previous year's figure of $-0.01 per share and indicates a positive trend for the company. Additionally, the company demonstrated growth in terms of revenue, with a sharp increase to $0.01 million fro...

Axim Biotechnologies Inc Surprises Market with Revenue of $0.009929 Million, but Faces Mounting Net Shortfall of $-3.723 Million

Axim Biotechnologies Inc is a biotechnology company that recently reported a revenue of $0.009929 million in the second quarter of 2023. Despite this positive revenue, the company experienced a net shortfall of $-3.723 million, which is higher compared to $-1.223 million in the same period last year.
This significant increase in net shortfall is a concerning factor for Axim Biotechnologies Inc. However, it is important to note that financial results can fluctuate throughout the year, and it is possible that the company can make improvements in the future. Investors will need to keep a close eye on the company's financial performance to assess if these shortfalls continue or if the company can recover in ...

AXIM Biotechnologies Reports Remarkable Revenue Uptick in Q1 Report of 2023

Axim Biotechnologies Inc, a leading biotech company, has recently announced its revenue results for the financial year closing on March 31, 2023. According to the report, the company's revenue for this period has been $0.007397 million. While this figure may seem small, it is a positive sign that the company is generating revenue even in a challenging economic environment.
However, the financial results for Axim Biotechnologies Inc are not entirely positive. The net shortfall for the company for this financial year was $-2.763 million, which is significantly higher than the previous year's net shortfall of $-2.087 million. This is a cause for concern, as a growing net shortfall generally implies that the...


Date modified: 2023-11-21T23:05:36+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com